Bone marrow glycophorin‐positive erythroid cells of myelodysplastic patients responding to high‐dose rHuEPO therapy have a different gene expression pattern from those of nonresponders

Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Nicola Stefano Fracchiolla(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Caterina Pellegrini(University of Milan), Ilaria Silvestris(University of Milan), Gualtiero I. Colombo(Centro Cardiologico Monzino), Silvano Bòsari(Ospedale Maggiore), L. Moronetti Mazzeo(University of Milan)
American Journal of Hematology
February 14, 2008
10.1002/ajh.21178
Cited by 10

Related Papers

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study
|The Lancet Haematology|2020|553
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)
|Blood|2009|433
Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non–High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial
|Journal of Clinical Oncology|2016|394
Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients
|Blood|2014|373
Angiogenesis in myelodysplastic syndromes
|British Journal of Cancer|1999|272